FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766382617> ?p ?o ?g. }

• W2766382617 endingPage "e0187173" @default.
• W2766382617 startingPage "e0187173" @default.
• W2766382617 abstract "Background Dysregulation of the Src pathway has been shown to be important at various stages of cancer. Dasatinib is a potent Src/Abl inhibitor and has demonstrated to have anti-proliferative and anti-invasive activity in many preclinical models. The objective of this study was to determine the anti-tumor activity of dasatinib using in vitro and in vivo preclinical colorectal (CRC) models. Methods CRC cell lines and patient-derived tumor explant (PDX) models were used to investigate the efficacy of dasatinib. We treated 50 CRC cell lines with dasatinib for 72 hours and proliferation was assayed by a sulforhodamine B (SRB) assay; an IC50 ≤ 0.08 μmol/L was considered sensitive. We treated 17 patient-derived CRC explants with dasatinib (50 mg/kg/day, administered once-daily) for 28 days to determine in vivo efficacy. Tumor growth inhibition (TGI) ≥ 50% was considered sensitive. Results We found that 8 out of 50 CRC cell lines reached an IC50 ≤ 0.08 μmol/L with dasatinib treatment. In addition, of 17 CRC explants grown in the xenograft mouse model, 2 showed sensitivity to dasatinib. The anti-tumor effects observed in this study were a result of G1 cell cycle arrest as the dasatinib sensitive CRC cell lines exhibited G1 inhibition. Moreover, those CRC cell lines that were responsive (0.08 μmol/L) to treatment demonstrated a significant baseline increase in Src and FAK gene expression. Conclusion Dasatinib demonstrated significant anti-proliferative activity in a subset of CRC cell lines in vitro, especially in those with increased Src expression at baseline, but only showed modest efficacy in CRC explants. Dasatinib is currently being studied in combination with chemotherapy in patients with advanced CRC, as its use as a single agent appears limited." @default.
• W2766382617 created "2017-11-10" @default.
• W2766382617 creator A5003463083 @default.
• W2766382617 creator A5004939243 @default.
• W2766382617 creator A5005047542 @default.
• W2766382617 creator A5008267854 @default.
• W2766382617 creator A5018557950 @default.
• W2766382617 creator A5019556057 @default.
• W2766382617 creator A5025510544 @default.
• W2766382617 creator A5036784999 @default.
• W2766382617 creator A5048304969 @default.
• W2766382617 creator A5051579199 @default.
• W2766382617 creator A5067509440 @default.
• W2766382617 creator A5073287784 @default.
• W2766382617 creator A5078259926 @default.
• W2766382617 creator A5086504706 @default.
• W2766382617 date "2017-11-01" @default.
• W2766382617 modified "2023-10-15" @default.
• W2766382617 title "Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model" @default.
• W2766382617 cites W1975972551 @default.
• W2766382617 cites W1978165300 @default.
• W2766382617 cites W1986901779 @default.
• W2766382617 cites W1988212593 @default.
• W2766382617 cites W1990915902 @default.
• W2766382617 cites W2030565228 @default.
• W2766382617 cites W2032775411 @default.
• W2766382617 cites W2032847998 @default.
• W2766382617 cites W2036988959 @default.
• W2766382617 cites W2041191688 @default.
• W2766382617 cites W2050973237 @default.
• W2766382617 cites W2054177711 @default.
• W2766382617 cites W2068994296 @default.
• W2766382617 cites W2076718022 @default.
• W2766382617 cites W2091656640 @default.
• W2766382617 cites W2092343827 @default.
• W2766382617 cites W2097208900 @default.
• W2766382617 cites W2102460196 @default.
• W2766382617 cites W2143060756 @default.
• W2766382617 cites W2143974518 @default.
• W2766382617 cites W2150310014 @default.
• W2766382617 cites W2159811154 @default.
• W2766382617 cites W2165688675 @default.
• W2766382617 cites W2166127280 @default.
• W2766382617 cites W2167084563 @default.
• W2766382617 cites W2332502334 @default.
• W2766382617 cites W2339356822 @default.
• W2766382617 cites W2526078043 @default.
• W2766382617 cites W4251916233 @default.
• W2766382617 doi "https://doi.org/10.1371/journal.pone.0187173" @default.
• W2766382617 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5665512" @default.
• W2766382617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29091939" @default.
• W2766382617 hasPublicationYear "2017" @default.
• W2766382617 type Work @default.
• W2766382617 sameAs 2766382617 @default.
• W2766382617 citedByCount "22" @default.
• W2766382617 countsByYear W27663826172018 @default.
• W2766382617 countsByYear W27663826172019 @default.
• W2766382617 countsByYear W27663826172020 @default.
• W2766382617 countsByYear W27663826172021 @default.
• W2766382617 countsByYear W27663826172022 @default.
• W2766382617 countsByYear W27663826172023 @default.
• W2766382617 crossrefType "journal-article" @default.
• W2766382617 hasAuthorship W2766382617A5003463083 @default.
• W2766382617 hasAuthorship W2766382617A5004939243 @default.
• W2766382617 hasAuthorship W2766382617A5005047542 @default.
• W2766382617 hasAuthorship W2766382617A5008267854 @default.
• W2766382617 hasAuthorship W2766382617A5018557950 @default.
• W2766382617 hasAuthorship W2766382617A5019556057 @default.
• W2766382617 hasAuthorship W2766382617A5025510544 @default.
• W2766382617 hasAuthorship W2766382617A5036784999 @default.
• W2766382617 hasAuthorship W2766382617A5048304969 @default.
• W2766382617 hasAuthorship W2766382617A5051579199 @default.
• W2766382617 hasAuthorship W2766382617A5067509440 @default.
• W2766382617 hasAuthorship W2766382617A5073287784 @default.
• W2766382617 hasAuthorship W2766382617A5078259926 @default.
• W2766382617 hasAuthorship W2766382617A5086504706 @default.
• W2766382617 hasBestOaLocation W27663826171 @default.
• W2766382617 hasConcept C108636557 @default.
• W2766382617 hasConcept C109316439 @default.
• W2766382617 hasConcept C121608353 @default.
• W2766382617 hasConcept C126322002 @default.
• W2766382617 hasConcept C150903083 @default.
• W2766382617 hasConcept C170493617 @default.
• W2766382617 hasConcept C202751555 @default.
• W2766382617 hasConcept C207001950 @default.
• W2766382617 hasConcept C2776074239 @default.
• W2766382617 hasConcept C2777583451 @default.
• W2766382617 hasConcept C2778729363 @default.
• W2766382617 hasConcept C2779536868 @default.
• W2766382617 hasConcept C502942594 @default.
• W2766382617 hasConcept C526805850 @default.
• W2766382617 hasConcept C54355233 @default.
• W2766382617 hasConcept C55493867 @default.
• W2766382617 hasConcept C62112901 @default.
• W2766382617 hasConcept C71924100 @default.
• W2766382617 hasConcept C81885089 @default.
• W2766382617 hasConcept C86803240 @default.
• W2766382617 hasConcept C98274493 @default.

• next